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ABSTRACT: (R)-[11C]verapamil is a radiotracer widely used for
the evaluation of the P-glycoprotein (P-gp) function at the blood−
brain barrier (BBB). Several studies have evaluated the
pharmacokinetics of (R)-[11C]verapamil in rats and humans
under different conditions. However, to the best of our knowledge,
the pharmacokinetics of (R)-[11C]verapamil have not yet been
evaluated in nonhuman primates. Our study aims to establish (R)-
[11C]verapamil as a reference P-gp tracer for comparison of a
newly developed P-gp positron emission tomography (PET) tracer
in a species close to humans. Therefore, the study assesses the
kinetics of (R)-[11C]verapamil and evaluates the effect of scan
duration and P-gp inhibition on estimated pharmacokinetic
parameters. Three nonhuman primates underwent two dynamic
91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-
[11C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-
corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations
(10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors
(SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[11C]verapamil data at baseline
and after inhibition and for all scan durations tested. The volume of distribution (VT) and the efflux constant k2 estimations were
affected by the evaluated scan durations, whereas the influx constant K1 estimations remained relatively constant. After P-gp
inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain VT increased significantly up to 208% (p < 0.001) and
K1 up to 159% (p < 0.001) compared with baseline scans. The k2 values decreased significantly after P-gp inhibition in all the scan
durations except for the 91 min scans. This study suggests the use of K1, calculated with 1-TCM and using short PET scans (10 to 30
min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates.
KEYWORDS: ABC transporters, brain imaging, efflux transporters, kinetics, P-gp tracers, rhesus monkeys
1. INTRODUCTION
(R)-[11C]verapamil is a radiotracer used to assess the P-
glycoprotein (P-gp) function at the blood−brain barrier
(BBB). Verapamil is a calcium channel blocker that is used
in the treatment of cardiovascular diseases such as hyper-
tension and arrhythmias,1 and it is also characterized as a
substrate for the efflux transporter P-gp. Therefore, [11C]-
verapamil has been used to assess the P-gp function in the
human brain by positron emission tomography (PET).2,3
P-gp is a transmembrane protein that belongs to the ATP
binding cassette transporter family. This transporter uses the
energy provided by hydrolysis of ATP to move endogenous
and exogenous compounds across the membranes.4 The P-gp
transporter at the BBB is expressed at the luminal side of the
endothelial cells, where it pumps a wide variety of substances
from the brain to the blood, protecting the central nervous
system (CNS) from harmful damage.5 P-gp dysfunctions have
been related to the onset and progression of several
neurodegenerative diseases and psychiatric disorders.6−8
Furthermore, numerous unrelated CNS drugs are P-gp
substrates and, therefore, dysfunction in the P-gp transporter
can alter the concentration of these drugs in the brain, causing
toxicity issues or decreases in drug efficacy.9,10 Thus, it is of
interest to evaluate the P-gp function in vivo with PET imaging,
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which is a noninvasive technique and an excellent tool for
quantification of biological processes.11−13 The P-gp function
was evaluated for the first time in 1996 using a racemic mixture
of [11C]verapamil,2 and since then, the P-gp function has been
extensively studied in humans with this tracer.7,8,14−20
[11C]verapamil was first prepared and evaluated as a racemic
mixture.2 However, the (R) and (S)-verapamil enantiomers
showed differences in the rate of metabolism, affinity to
calcium channels, plasma protein binding, and clearance that
complicate the pharmacokinetic quantification of the racemic
tracer.14,21 Therefore, one of the enantiomers had to be
selected for labeling. As (R)-[11C]verapamil showed less radio-
metabolites and lower affinity to calcium channels than (S)-
[11C]verapamil, it was selected as the most adequate tracer for
measuring the P-gp function.21
Since then, several studies have reported the ability of (R)-
[11C]verapamil to measure the P-gp function.13 For instance,
after the administration of a P-gp inhibitor, the P-gp function is
decreased and, consequently, the radiotracer is accumulated
inside the brain.22−24 This tracer has a very high affinity for the
P-gp transporter and, therefore, at baseline conditions, when
the P-gp transporter is working adequately, the tracer uptake is
very low because the P-gp transporter pumps most of the
tracer out of the brain.11,25 Novel PET tracers with lower P-gp
affinity have been developed to achieve higher tracer uptake in
the brain at baseline conditions.10,11
The development of new P-gp tracers that have lower
affinity to the P-gp transporter (weak P-gp tracers)26,27
requires kinetic comparison with (R)-[11C]verapamil, which
is considered as the reference P-gp PET tracer because its
kinetics have been widely evaluated in rats and humans under
different conditions.16,28−30 This comparison may lead to a
greater understanding of the kinetic properties of weak and
avid substrates. Weak P-gp tracers, such as [11C]-
metoclopramide and [18F]MC225, have been evaluated in
rats and also in nonhuman primates that are more closely
related to humans biologically.26,27,31 However, to perform a
head-to-head comparison in nonhuman primates, a kinetic
modeling evaluation of (R)-[11C]verapamil needs to be
performed in monkeys first. So far, only the kinetics of
racemic [11C]verapamil were evaluated.32−34 One study has
assessed the kinetics of (R)-[11C]verapamil in rhesus monkeys,
but it did not provide a full kinetic evaluation of the tracer.35
This study aims to assess the kinetics of (R)-[11C]verapamil
tracer at baseline and after the inhibition of the P-gp function
using different scan durations (10, 20, 30, 60, and 91 min) and
exploring different compartmental models. Moreover, the
paper aims to determine the most suitable and reliable
parameter to measure the P-gp function (and its change) at the
BBB of nonhuman primates.
2. EXPERIMENTAL SECTION
2.1. Chemicals and Synthesis of the Tracer. Tariquidar
(MedChemExpress, New Jersey, USA) was used as a P-gp
inhibitor.24,29,36 Tariquidar solution for intravenous injection
was prepared as previously described,37 with 11 mg of
tariquidar methanesulfonate hydrate suspended in 3 mL of
saline solution, and the injection volume was adjusted to the
weight of each monkey (8 mg/kg of body weight). Radiosyn-
thesis and quality control of (R)-[11C]verapamil were
performed as described previously.21
2.2. Animals. Three healthy male rhesus monkeys (Macaca
mulatta; Hamri Co. Ltd., Ibaraki, Japan) were included in this
study that was performed at the Central Research Laboratory,
Hamamatsu Photonics (Hamamatsu, Japan), in collaboration
with the Tokyo Metropolitan Institute of Gerontology (Tokyo,
Japan). The animals were housed individually in a controlled
environment (24 ± 4 °C, 50 ± 20% of humidity under a 14 h
light/10 h dark cycle) and maintained and handled in strict
accordance with the recommendations of the National
Institute of Health and the guidelines of the Ethics Committee
of the Central Research Laboratory, Hamamatsu Photonics
(approval HPK-2016-07A), and the Institutional Animal Care
and Use Committee of Tokyo Metropolitan Institute of
Gerontology (approval 16067).
2.3. Data Collection. 2.3.1. Experimental Design. Each
nonhuman primate underwent two PET scans with (R)-
[11C]verapamil. One was performed at baseline conditions and
the second one after the inhibition of the P-gp function with
tariquidar. The time interval between the scans was 2 h, except
for one animal where it was 2 months due to technical issues.
Tariquidar was slowly injected through a catheter inserted into
a saphenous vein 15 min before the PET scans at a dose of 8
mg/kg of body weight. Table 1 shows the body weight of the
monkeys on the scanning day, the day of the scan, and the
hour of radiotracer injection.
2.3.2. PET Imaging Acquisition and Reconstruction. The
same acquisition protocol was used in a previous study.37
Briefly, 1 week before the first PET scan, a brain T1-weighted
magnetic resonance imaging (MRI) scan of the animal was
made (Signa Excite HDTx 3.0T, GE Healthcare).38 Brain PET
scans were acquired using a high-resolution animal PET
scanner (SHR-38000, Hamamatsu Photonics). All nonhuman
primates underwent dynamic PET scans with arterial blood
sampling. Monkeys were anesthetized (2.5% sevoflurane)
during the arterial cannulation and their transport, but they
were awake during the scans and the head was immobilized
using a fixation device. The animals were positioned in the
camera in a sitting position with stereotactic coordinates
aligned paralleled to the orbitomeatal plane.
Prior to tracer injection, a rotating 68Ge/68Ga rod source was
used to perform the transmission scan (60 min), and its
information was used for attenuation correction of the PET
images. Next, animals were injected with (R)-[11C]verapamil
(more information in Table 2) at the start of the emission scan
(91 min) via the saphenous vein over a period of 30 s as a
single bolus.
PET images were reconstructed using the filtered back
projection method with a Hanning filter of 4.5 mm in SHR-
38000 Reconstruction software (Hamamatsu Photonics) and
were composed of 49 frames (6 × 10, 6 × 30, 12 × 60, and 25
× 180 s).













subject 1 baseline 27/12/2016 10:59 8.2
subject 1 after inhibition 27/12/2016 14:45 8.2
subject 2 baseline 17/02/2017 11:01 6.1
subject 2 after inhibition 17/02/2017 14:03 6.1
subject 3 baseline 28/02/2017 12:45 7.2
subject 3 after inhibition 26/12/2016 14:01 6.6
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2.3.3. Arterial Blood Sampling. As has been described
before,37 after the administration of the tracer, 19 blood
samples (0.5 mL) were drawn from a cannula placed in the
posterior tibial artery at selected time points (8, 16, 24, 32, 40,
48, 56, and 64 s and 1.5, 2.5, 4, 6, 10, 20, 30, 45, 60, 75, and 90
min). Then, the plasma and blood were separated by
centrifugation (12,000 rpm, 60 s), and the radioactivity was
measured using a gamma counter (1480 Wizard, PerkinElmer).
The total amount of blood removed from the animal was less
than 35 mL/day in each animal.
2.3.4. Metabolite Analysis. Parent fraction and polar
radioactive metabolites of (R)-[11C]verapamil in arterial
blood samples were determined following the tracer injection
(16, 40, and 64 s and 6, 10, 30, 45, 60, 75, and 90 min). A 0.2
mL volume of ethanol was added to the 0.1 mL of plasma
fraction to deproteinize the samples. After centrifugation
(13,400 rpm,12,100g, for 90 s), the samples were analyzed
using thin-layer chromatography plates (silica gel 60 F254,
Merk) with a mobile phase of ethyl acetate/trimethylamine
(9/1). The parent (Rf = 0.55) and polar-metabolized (Rf =
0.0, origin) fractions were assessed using a phosphor imaging
plate and a bioimaging analyzer (FLA-7000, Fuji Film).
The percentage of the polar radio-metabolites in plasma was
calculated for each animal by fitting a single exponential
equation to the values obtained from the metabolite analysis,
using an iterative nonlinear least-squares approach (GraphPad
Prism version 7.02, California, USA): Y = Y0 × exp(−Ke ×
X),39 where Y is the percentage of the parent tracer at different
time points, Y0 is the intercept, Ke is the first-order elimination
constant, and X is the time.
2.4. Analysis of PET Data. 2.4.1. Time−Activity Curves of
Blood Sampling: Input Function. Time−activity curves
(TACs) were determined using the activity of the whole
blood and plasma and expressed as a standardized uptake value
(SUV): SUV = radioactive concentration/(injected dose/body
weight). The radioactivity measured in blood samples was
corrected for decay from the time point of tracer
administration. The plasma SUV−TAC corrected for polar
radio-metabolites (i.e., metabolite-corrected plasma) was
calculated by multiplying the SUV values of plasma samples
by the percentage of parent tracer.
A single exponential equation was fitted to the radio-
metabolite-corrected SUV−TAC individually using the values
after the peak (from 360 to 5400 s) by an iterative nonlinear
least-squares approach (GraphPad Prism version 7.02,
California, USA): Y = Y0 × exp(−Ke × X), where Y represents
the SUV values at different time points, Y0 is the intercept, Ke
is the first-order elimination constant, and X is the time. This
approach allows the determination of the rate of tracer
elimination (Ke) and the biological half-life (T1/2): T1/2 =
ln(2)/Ke.
40
2.4.2. PET/MRI Analysis. Images were processed using
PMOD v3.8 software (PMOD Technologies, Zürich, Switzer-
land). All the scans were registered to a reference MRI
template41−43 as previously described37 and the following
volumes of interest (VOI) were selected for further analysis:
basal ganglia, brainstem, cerebellum, cingulate cortex, orbito-
frontal cortex, hippocampus, hypothalamus, insular cortex,
midbrain, occipital cortex, parietal cortex, striatum, temporal
cortex, thalamus, white matter, and a VOI covering the whole
brain. This registration procedure and region analysis have
been previously described.37
The registration of the images was performed as follows.
First, the MRI of the animal was registered to the reference
MRI using a 3 probability maps normalization.44 Then, (R)-
[11C]verapamil PET images were aligned to their correspond-
ing MRI by rigid transformation using a summation of all
frames. For baseline scans, the (R)-[11C]verapamil after-
inhibition PET images were used as a reference because of
the difficulties in the registration of MRI with the baseline PET
images (the latter showing lack of anatomical information in
the image and limited brain radiotracer uptake).
2.4.3. Pharmacokinetic Analysis. Several models were
fitted to the VOI TACs, with the plasma-corrected for polar
radio-metabolites (metabolite-corrected plasma) or non-
corrected plasma TACs and the whole-blood TACs as the
input function. The pharmacokinetic modeling was performed
using PMOD v3.8 software.
First of all, the input functions from each animal were
corrected for blood delay. The blood delay was calculated
using the whole-brain TAC, and then this value was fixed for
the rest of the regions. The compartmental models evaluated
were the 1-tissue compartment model (1-TCM), the 2-tissue
compartmental model (2-TCM), and the irreversible 2-TCM.
All the models were assessed using either a fixed fractional
blood volume (vB) (3, 4, 5, 6, or 7%) or using vB as a fit
parameter. Data sets with different scan durations (10, 20, 30,
60, and 91 min) were analyzed in order to explore its effect on
the model preference and the parameter’s estimates. The
compartmental model analyses were performed twice, once
with the plasma-corrected for polar radio-metabolites and then
with the plasma non-corrected for radio-metabolites as the
input function. No boundary restrictions were applied for the
fit of the parameters during the kinetic analysis.
Akaike information criterion (AIC) was used to choose the
most optimal kinetic model for each scan duration and type of
scan (baseline or after inhibition). The standard errors (SE %)
of the estimated parameters were also taken into consideration
during model selection.
Several common kinetic parameters, that is, the influx
constant K1, the volume of distribution (VT), and the efflux
constant k2, were compared between baseline and after-
Table 2. Subject Information and Properties of (R)-[11C]verapamil
(R)-[11C]verapamil
nonhuman primates scan body weight (kg) injected dose (MBq) molar activity (GBq/μmol) injected mass (nmol)
subject 1 baseline 8.2 893.6 118.2 7.6
subject 1 after inhibition 8.2 919.3 80.6 11.4
subject 2 baseline 6.1 968.8 20.5 47.4
subject 2 after inhibition 6.1 981.8 49.5 19.8
subject 3 baseline 7.2 1020.2 55.5 18.4
subject 3 after inhibition 6.6 941.1 85.3 11.0
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inhibition scans to evaluate the effect of inhibition and to select
the most appropriate parameter to measure the P-gp function.
2.5. Parametric Images. Parametric images of K1, VT, and
k2 at baseline and after inhibition were calculated in one
Figure 1. (A) Metabolite-corrected plasma TACs of baseline (blue) and after-inhibition (green) scans (SUV). (B) Percentage of parent fraction at
baseline (blue) and after inhibition (green).
Figure 2. AIC in whole brain using different models for all the scan durations at baseline (blue) and after-inhibition (green) scans. Mean values ±
SE are plotted.
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monkey (subject 2) for representation purposes. The
metabolite-corrected plasma TAC was used as an input
function for the basis function implementation of 1-TCM
using PMOD v3.8 software.
2.6. Statistical Analysis. Inferential results are reported as
estimated marginal mean ± SE (mean ± SE) unless mentioned
otherwise. Statistical analysis was performed using IBM SPSS
Statistics version 23 (Armonk, NY, USA). Differences in
kinetic parameter values and Akaike values among models,
scan durations, and type of scans (baseline or after-inhibition)
were assessed independently for each brain region by the
generalized estimated equation (GEE) model using an
independent working correlation matrix.45,46 The GEE is
recommended for the analysis of longitudinal data and it is also
more efficient, achieving higher power with a small sample
size.47 The relationship between the estimated parameters
calculated with different models and different data sets was
explored by linear regression analysis. Results were considered
statistically significant at p < 0.05, without correction for
multiple comparisons. The differences between baseline and
after inhibition are reported as a percentage and calculated as
follows: 100 × (after-inhibition − baseline)/baseline.
3. RESULTS
3.1. Tracer Production. Molar activities and radio-
chemical purities of (R)-[11C]verapamil productions as well
as the mass and radioactive dose injected in each animal are
reported in Table 2.
3.2. Input Function and Metabolism of (R)-[11C]-
verapamil. A significant increase in the area under the curve
(AUC) of the whole-blood TACs was found after the
administration of the P-gp inhibitor tariquidar (baseline =
2.03 ± 0.33 vs after inhibition = 2.22 ± 0.35, p = 0.041). No
statistically significant differences between baseline and after-
inhibition scans were found in the uncorrected or metabolite-
corrected plasma TACs (Figure 1). However, a statistically
significant reduction of the % parent fraction of (R)-
[11C]verapamil was found after the P-gp inhibition (75.25 ±
1.37%, p = 0.019) compared to baseline values (79.82 ±
Figure 3. K1 (A), k2 (B), and VT (C) in whole brain at baseline (blue) and after inhibition (green), estimated from scans with different durations.
Mean values ± SE are plotted.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c01014
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
E
1.26%). The Ke and T1/2 of (R)-[
11C]verapamil did not
significantly change after the P-gp inhibition.
3.3. Plasma Input Models: Compartmental Models.
3.3.1. Blood Volume Fraction. After correcting the whole-
blood and plasma TACs for blood delay, the fractional vB was
either fixed to 3, 4, 5, 6, and 7% or used as a fit parameter.
According to the AIC, the best fits were obtained when vB was
used as a fit parameter, which provided values ranging between
4 and 6%. Moreover, the SE % of the estimated parameters was
also lower when vB was fitted rather than fixed. Similar results
were obtained when vB was fixed to 5%. Supporting
Information Figure S1 shows boxplots of AIC values and SE
% K1 values for the whole brain using different scan durations
and models. Because fixing vB did not improve the fits, the
following analyses have been performed using vB as the fit
parameter.
3.3.2. Model Selection for Different Scan Durations. The
1-TCM and 2-TCM fits showed similar AIC values in short
scans, but in scans longer than 60 min, the lowest Akaike
values were found using 2-TCM. Figure 2 shows the AIC for
the whole brain for all tested scan durations and both scans
(baseline and after inhibition) obtained with 1-TCM, 2-TCM,
and irreversible 2-TCM.
For the 60 min scan, even though the lowest AIC values
were found using 2-TCM, the model showed very large SE %
(>100%) in the estimation of k2, k4, and VT. For instance, the
mean SE % VT of the whole brain at baseline using 60 min scan
duration was 14,898 ± 12,158. Using 2-TCM, the SE % VT
values were in 35 cases (out of 96) higher than 100% and in 22
higher than 1000%. In the case of 91 min scan duration, 2-
TCM provided lower AIC values than 1-TCM; however, some
regions showed unreliable values. In 13 cases (out of 96), the
SE % VT were higher than 100% and in three cases higher than
1000%. For these reasons, 1-TCM (which showed lower SE
%) was selected as the most robust model to analyze the data
for all scan durations. Supporting Information Figure S2 shows
representative 1-TCM and 2-TCM fits for the 30 and 91 min
scans of the whole brain.
3.3.3. Effect of Scan Duration. Based on our findings
described above, 1-TCM was used to fit the PET data for all
tested scan durations. The evaluated scan durations did not
affect significantly K1 estimations (3−13%), at least during the
first 60 min of the scan. However, the estimation of k2
decreased and the VT increased with longer scan durations in
both baseline and after-inhibition scans. In Figure 3, the effect
of scan duration on the kinetic parameters of the whole brain
in baseline and after-inhibition scans is shown.
Table 3. Changes in VT, K1, and k2 after P-gp Inhibition in Brain Regions using 30 and 91 min Scan Durations and 1-TCM
a
scan duration regions K1 ± SE (%) p values VT ± SE (%) p values k2 ± SE (%) p values
% of Changes between Baseline and after-Inhibition Scan in 30 min Scan
30 min basal ganglia 156 ± 45 <0.001 244 ± 38 <0.001 −25 ± −4 <0.001
brainstem 176 ± 46 <0.001 241 ± 33 <0.001 −19 ± −2 0.008
cerebellum 141 ± 37 <0.001 276 ± 42 <0.001 −35 ± −4 <0.001
cingulate cortex 138 ± 32 <0.001 294 ± 41 <0.001 −40 ± −4 <0.001
orbitofrontal cortex 93 ± 28 <0.001 190 ± 39 <0.001 −33 ± −3 <0.001
hippocampus 146 ± 35 <0.001 227 ± 32 <0.001 −25 ± −3 <0.001
hypothalamus 158 ± 44 <0.001 270 ± 39 <0.001 −30 ± −4 <0.001
insular cortex 152 ± 38 <0.001 294 ± 36 <0.001 −35 ± −5 <0.001
midbrain 205 ± 57 <0.001 305 ± 49 <0.001 −25 ± −4 <0.001
occipital cortex 130 ± 29 <0.001 268 ± 35 <0.001 −37 ± −4 <0.001
parietal cortex 127 ± 31 <0.001 247 ± 34 <0.001 −34 ± −4 <0.001
striatum 168 ± 45 <0.001 267 ± 40 <0.001 −27 ± −3 <0.001
temporal cortex 143 ± 41 <0.001 242 ± 39 <0.001 −28 ± −4 <0.001
thalamus 176 ± 41 <0.001 285 ± 33 <0.001 −28 ± −4 <0.001
white matter 145 ± 36 <0.001 268 ± 38 <0.001 −33 ± −4 <0.001
whole brain 136 ± 34 <0.001 252 ± 37 <0.001 −33 ± −4 <0.001
% of Changes between Baseline and after-Inhibition Scan in 91 min Scan
91 min basal ganglia 174 ± 46 <0.001 210 ± 42 <0.001 −11 ± −1 0.059
brainstem 199 ± 48 <0.001 199 ± 32 <0.001 1 ± 0 0.855
cerebellum 167 ± 41 <0.001 231 ± 43 <0.001 −18 ± −2 0.013
cingulate cortex 166 ± 37 <0.001 237 ± 43 <0.001 −21 ± −2 0.041
orbitofrontal cortex 111 ± 30 <0.001 153 ± 40 <0.001 −16 ± −2 0.049
hippocampus 162 ± 37 <0.001 198 ± 35 <0.001 −13 ± −2 0.160
hypothalamus 184 ± 46 <0.001 215 ± 43 <0.001 −9 ± −1 0.224
insular cortex 177 ± 40 <0.001 246 ± 43 <0.001 −19 ± −2 0.004
midbrain 228 ± 62 <0.001 267 ± 52 <0.001 −11 ± −2 0.314
occipital cortex 155 ± 34 <0.001 221 ± 34 <0.001 −20 ± −2 0.018
parietal cortex 148 ± 34 <0.001 204 ± 36 <0.001 −18 ± −2 0.076
striatum 193 ± 47 <0.001 220 ± 41 <0.001 −8 ± −1 0.293
temporal cortex 165 ± 43 <0.001 199 ± 41 <0.001 −10 ± −1 0.112
thalamus 200 ± 43 <0.001 243 ± 39 <0.001 −12 ± −1 0.222
white matter 170 ± 39 <0.001 223 ± 41 <0.001 −16 ± −2 0.094
whole-brain 159 ± 37 <0.001 208 ± 40 <0.001 −15 ± −2 0.072
aMean values ± SE are listed, changes are shown as percentages.
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VT was most affected by the scan duration. In baseline scans,
VT increased by 61% from 2.16 ± 0.24 in a 10 min scan to 3.48
± 0.38 (p < 0.001) in a 91 min scan. Similarly, in after-
inhibition scans, the VT increased by 40% from 7.88 ± 0.20 in
10 min to 10.99 ± 0.85 (p < 0.001) in a 91 min scan. The
baseline VT in the 60 min scan also increased by 40% (p <
0.001) and in after-inhibition scans by 29% (p < 0.001)
compared to the values in the 10 min scan. The baseline k2
decreased by 51% in a 91 min scan and by 36% in after-
inhibition scans compared to a 10 min scan.
3.3.4. Effect of P-gp Inhibition. The vB estimated by the
model was not significantly different between baseline and
after-inhibition scans for any of the scan durations, except for
the 10 min scan duration where the estimated vB significantly
increased from 0.049 ± 0.001 at baseline to 0.052 ± 0.001 after
P-gp inhibition (p = 0.018).
Figure 4. Mean ± SE of K1 for all brain regions at baseline and after-inhibition scans with different durations.
Figure 5. Parametric images of one subject using the 91 min scan data at baseline (A) and after inhibition (B), representing K1 (mL/cm
3/min,
above), k2 (1/min, center), and VT (below).
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In all scan durations, the parameter most affected by P-gp
inhibition was VT. In 91 min scans, the whole-brain VT
increased by 208% after P-gp inhibition; meanwhile, the K1
increased by 159% in after-inhibition scans. The k2 of the
whole brain decreased by 15%. In all scan durations, VT and K1
significantly increased in all the brain regions after P-gp
inhibition. Meanwhile, k2 significantly decreased in all scan
durations except for the 91 min scan. Table 3 shows the
changes in VT, K1, and k2 after the P-gp inhibition in all the
brain regions using 30 and 91 min scan durations.
The magnitude of changes is dependent on scan duration
because estimated values of VT and k2 are different in short and
long scans. Figure 4 and Supporting Information Figures S3
and S4 show the mean values of K1, VT, and k2 at baseline and
after inhibition.
For illustrative purposes, Figure 5 shows VT, K1, and k2
parametric images of one subject (subject 2) at baseline and
after inhibition using 91 min scan and metabolite-corrected
plasma as the input function.
3.3.5. Correlation K1−VT. In 60 and 91 min scans, K1 and VT
showed a good correlation at baseline (R2 = 0.74 and R2 =
0.61, p < 0.01) and after-inhibition scans (R2 = 0.70 and R2 =
0.76, p < 0.01, respectively). Figure 6 shows the correlation
between K1 and VT in 60 and 91 min scan for baseline and
after-inhibition scans.
3.4. Plasma Non-corrected for Radio-Metabolite
Input Models: Compartmental Models. The compartmen-
tal analyses were also performed using the plasma radioactivity
non-corrected for radio-metabolites as an input function for 1-
TCM in all scan durations. For most of the brain regions
analyzed, the SE % of K1, k2, and VT was higher when using the
plasma radioactivity non-corrected for radio-metabolites than
with plasma-corrected for polar radio-metabolites. In 91 min
scan durations, the overall SE % VT was 471% higher than the
one obtained with the corrected plasma. Moreover, VT values
obtained with non-corrected plasma were significantly lower
than the ones obtained with plasma radioactivity corrected for
polar radio-metabolites, especially in after-inhibition scans (e.g.,
Figure 6. Correlation between K1 and VT obtained with 1-TCM using 60 (A) or 91 min (B) data at baseline (blue) and after inhibition (green).
Figure 7. k2 (A) and VT (B) at different scan durations at baseline and after inhibition using different input functions (plasma-corrected for radio-
metabolites or plasma-non-corrected). Mean values ± SE are plotted.
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in 91 min after-inhibition scans VT non-corrected plasma =
3.97 ± 0.27 vs. VT corrected plasma = 10.87 ± 0.82; p <
0.001). The k2 values obtained with non-corrected plasma were
higher than in corrected plasma in both baseline and after-
inhibition scans, and the differences were more pronounced at
long scan duration (>60 min). For instance, in a 91 min scan,
the mean k2 after inhibition obtained with non-corrected
plasma was 0.13 ± 0.014 1/min, and with corrected plasma, it
was 0.036 ± 0.001 1/min (p < 0.001).
Regarding the effect of scan duration, the estimations of VT
decreased and k2 increased with the scanning time when
plasma non-corrected for radio-metabolites was used as the
input function, whereas when plasma radioactivity was
corrected for polar radio-metabolites, the estimations of VT
increased and k2 decreased (see Figure 7). Nevertheless,
regarding P-gp inhibition, similar results were obtained
compared to the analysis with metabolite-corrected plasma.
The administration of tariquidar significantly increased K1 and
VT at all scan durations. However, the analysis did not find
significant changes in k2 after the P-gp inhibition. At 91 min
scan duration, K1 increased from 0.20 ± 0.03 mL/cm
3/min at
baseline to 0.51 ± 0.06 mL/cm3/min after inhibition (p <
0.001) and VT from 1.71 ± 0.22 at baseline to 3.97 ± 0.27 after
P-gp inhibition (p < 0.001).
4. DISCUSSION
The aim of this study was to evaluate the kinetics of the P-gp
tracer (R)-[11C]verapamil in baseline conditions and after P-gp
inhibition in nonhuman primates. Moreover, the study also
evaluates the kinetics at different acquisition times (10 to 91
min) to assess the effect of the scan duration on the estimated
parameters. Our results showed that 1-TCM with fractional vB
as a fit parameter is the most suitable compartment model to
fit the data at baseline and after-inhibition conditions for all the
scan durations tested.
Model preferences seem not to be influenced by the scan
duration. Although in the case of long scan durations (>60
min), the lowest AIC were seen with 2-TCM, large SE %
(>100%) of the estimated parameters (VT, k2, and k4) were
found. These large SE % did not provide reliable VT values in
several brain regions using 60 and 91 min scan durations.
Several adjustments were applied to the model fit in an attempt
to solve this problem. For instance, the use of 2-TCM while
fixing the ratio K1/k2 to the whole brain gray matter value, as
was suggested for the analysis of (R)-[11C]verapamil in
humans,19 or by imposing a lower boundary for the k4
(0.001 1/min). However, none of these strategies improved
the quality of the 2-TCM fit (results not reported). We have
also tested a 2-input-compartmental model where we applied
both a parent tracer and radio-metabolites plasma input curve
at the same time in the model. This model has been already
used in previous studies to account for the entrance of radio-
metabolites of [11C]verapamil in the brain.48 However, when
using this model, we found large uncertainties in the estimated
kinetic parameters (K1, k2, and VT) (with SE % > 100%) in
most of the brain regions analyzed (data not shown). The 2-
input model did not provide reliable and robust results for our
data and was therefore not explored in our paper. Therefore, 1-
TCM was selected as the model of choice to analyze the (R)-
[11C]verapamil data in nonhuman primates for all tested scan
durations and for both baseline and after-inhibition scans.
Although different kinetic analysis methods have been
previously studied, a clear consensus regarding the optimal
method has not yet been reached.14,19,23,49 In rats, 2-TCM
showed better fits than 1-TCM for both baseline and after
tariquidar administration scans. Thus, it was selected as the
model of choice using either plasma-corrected for polar radio-
metabolites or plasma non-corrected for radio-metabolites.22,50
In humans, several approaches have been applied to fit the (R)-
[11C]verapamil data.14 In healthy subjects, 1-TCM with vB as a
fit parameter and using a metabolite-corrected plasma input
function showed an adequate fit. 2-TCM was also applied;
however, the fit did not provide robust parameters.18 Next,
(R)-[11C]verapamil was also assessed after the administration
of tariquidar (P-gp after-inhibition scans); in this case, a 2-
TCM fit was preferred, whereas the data from baseline scans
(before the P-gp inhibition) was fitted with 1-TCM using a
plasma input function corrected for polar radio-metabolites.23
Muzi et al. used 1-TCM to fit the 10 min scan duration data
and 2-TCM for the 45 min scan for both baseline and after P-
gp inhibition scans and corrected the plasma input function for
polar and lipophilic radio-metabolites. In this study, Muzi et al.
recommended the use of 10 min scan data to avoid the
interference of radio-metabolites with the brain signal.49 Also,
in humans, the use of constrained 2-TCM (i.e., fixing the ratio
K1/k2 to the mean whole-brain gray matter value) was
proposed, with plasma-corrected for polar radio-metabolites
as the input function. The results of this analysis suggested that
constrained 2-TCM leads to more reproducible results in
healthy volunteers.19
In our study, the administration of the P-gp inhibitor
tariquidar caused a significant increase of VT and K1 in all the
brain regions analyzed. VT was the parameter most affected by
P-gp inhibition. Tariquidar treatment caused an increase in VT
of 257% (p < 0.001) in the 10 min scan, of 230% (p < 0.001)
in the 60 min scan, and an increase of 208% (p < 0.001) in 91
min scan compared to baseline. K1 was also affected by P-gp
inhibition. The changes in whole-brain K1 between baseline
and after-inhibition scans varied from 131% in 10 min scans to
159% in 91 min scans. Moreover, we also found a significant
reduction in whole-brain k2 at all the scan durations except for
the 91 min scan. k2 was decreased by 34% in 10 min (p <
0.001) scans and by 15% in 91 min scans (p = 0.072). These
results support the ability of (R)-[11C]verapamil to detect
changes in the P-gp function in nonhuman primates as has
been already proven in other species.
Various studies have been done in humans under baseline
and inhibition conditions.23,24 Three hours after the admin-
istration of 2 mg/kg of tariquidar by intravenous infusion over
30 min caused an increase of VT and K1 by 24 ± 15 and 49 ±
36%, respectively.23 Another study found that the admin-
istration of tariquidar as a continuous infusion during 1 h
before the PET scan and during the 60 min PET scan (total
infusion time 2 h and mean tariquidar dose 5.9 ± 1.0 mg/kg)
increased VT and K1 values by 273 ± 78 and 259 ± 74%,
respectively, relative to baseline scans.24 Although the
inhibition of the P-gp function also caused an increase in the
K1 and VT values in humans, the values of the kinetic
parameters, and the effect size are different from the monkeys’
values. However, because different doses of tariquidar, routes
of administration, and duration of the perfusion were used in
the monkeys, the human and monkey values cannot be directly
compared. In rats, the P-gp inhibition also caused an increase
in K1 and VT, but similar discrepancies were observed.
22,50
Previous studies have shown that lipophilic radio-metabo-
lites of (R)-[11C]verapamil have similar kinetics as the parent
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tracer; thus, most of the studies use the radiotracer
concentration in plasma-corrected for polar radio-metabolites
as the input function for the kinetic analysis.18,51 Our kinetic
analysis was performed using the radiotracer concentration in
plasma-corrected for polar radio-metabolites and non-
corrected for radio-metabolites as the input function. When
plasma non-corrected for radio-metabolites was used, large SE
% (>50%) in the parameter estimations was found. Therefore,
corrections for polar radio-metabolites should be performed to
avoid noisy data and low reliability of the estimated
parameters. For long scan durations, VT values calculated
with plasma non-corrected for radio-metabolites as input were
lower (40−60%) than with corrected plasma input, and k2
values were 100−260% higher. These lower VT values and the
decrease in VT estimations with increasing scan durations may
be caused by the higher radioactivity concentration in the
input function. Therefore, if the radioactivity in blood is not
corrected by the amount of radio-metabolites, the model
underestimates the VT values. When plasma-corrected for
metabolites are used as the input function, the estimated VT
should not vary with the scan duration. However, because the
plasma was only corrected by polar metabolites, it can be that
lipophilic metabolites also accumulate in the brain, which may
cause the increase in the VT estimations with longer scan
durations. Concerning the tariquidar administration, the
analysis using non-corrected plasma input showed a significant
increase in VT and K1 after P-gp inhibition as was also observed
when plasma-corrected for polar radio-metabolites was used. In
91 min scans, VT increased up to 132% (p < 0.001) in after-
inhibition scans relative to baseline and K1 up to 150% (p <
0.001). This similar effect of P-gp inhibition on K1 and VT may
allow avoiding the radio-metabolite analysis, which is
considered as a time-consuming and tedious process. However,
if changes in the metabolism of (R)-[11C]verapamil occur due
to a disease condition or administration of treatments, the
kinetic quantification can be incorrect. Therefore, the
correction of plasma radioactivity for polar radio-metabolites,
which have different kinetics than the parent fraction, should
be performed, as was also concluded from human studies.18
Our baseline VT values using either metabolite-corrected or
non-corrected plasma inputs were higher than those obtained
with rats.22,50 However, K1 values in rats and nonhuman
primates at baseline conditions were similar. In our study, the
mean whole-brain K1 value at baseline was 0.15 ± 0.02 mL/
cm3/min in 91 min scans using plasma-corrected for radio-
metabolites, whereas in rats, the K1 values calculated with 2-
TCM and plasma-corrected for polar radio-metabolites were
0.16 ± 0.05 mL/cm3/min.50 Compared with human data, the
K1 and VT values obtained in our study were also higher. The
baseline K1 values in humans were 0.034 ± 0.009 mL/cm
3/
min and increased to 0.049 ± 0.009 mL/cm3/min after P-gp
inhibition. The VT values in 40 min scans were 0.65 ± 0.13 at
baseline and 0.80 ± 0.07 after inhibition, as calculated with 2-
TCM.23 Compared with our 30 min scan duration data,
baseline K1 values in nonhuman primates were 429% higher
relative to humans, and the baseline VT values were 288%
higher. These different values could be caused by species
differences in the expression of P-gp at the BBB.52,53
Kinetic evaluation of another strong P-gp substrate tracer,
[11C]-N-desmethyl-loperamide ([11C]dLop), in nonhuman
primates before and after administration of the P-gp inhibitor
cyclosporine A,54 showed similar increases of brain uptake after
P-gp inhibition as were observed in our study. The evaluation
of [11C]dLop did not use compartmental models and,
therefore, the brain uptake was not calculated using the VT
but using the ratio between the AUC from the brain and the
AUC from the blood (AUCR = AUCbrain/AUCblood).
54 In this
study, the AUCR after the administration of the P-gp inhibitor
(15 mg/kg/h i.v.) was enhanced to 10.8 ± 3.6,54 which is
similar to our after-inhibition VT value of the whole brain of
10.87 ± 0.82.
With regard to the tracer kinetics in plasma, it is known that
(R)-[11C]verapamil suffers from extensive in vivo metabolism,
both in small animals and in humans. In the present study on
nonhuman primates, the percentage of parent tracer at 30 min
after the injection was 57% in baseline scans and 45% in after-
inhibition scans, after correction for polar radio-metabolites.
Regarding the differences in parent tracer between baseline
and after-inhibition scans, our analysis found a significant
reduction (6%) in the percentage of parent (R)-[11C]verapamil
in after-inhibition scans compared to baseline. In humans, the
percentage of parent tracer is around 45% at 1 h after the
injection.18 In rats, at 30 min after tracer injection, the fraction
of parent (R)-[11C]verapamil in plasma was 47%, and after 1 h,
it was 27%.55 Previous radio-metabolite studies with nonhu-
man primates, performed by high-performance liquid chroma-
tography, have already reported a strong metabolism of (R)-
[11C]verapamil with around 80% of plasma radioactivity
associated with radio-metabolites (polar and lipophilic radio-
metabolites) at 30 min after the injection.35 Therefore, the rate
of metabolism of (R)-[11C]verapamil appears to be rapid and
similar in different species.
Short PET scan durations are more convenient for the
subjects and also to simplify the kinetic evaluation by reducing
the impact of tracer metabolism. In our study, K1 values
slightly decreased (3−13%) with increasing scan duration but
remained relatively constant regardless of the scan duration
applied. VT was most affected by the scan duration. In the 91
min scan, VT increased up to 61% (p < 0.001) in baseline and
40% (p < 0.001) in after-inhibition scans compared to the
values obtained with 10 min scan duration. We also observed a
decrease in k2 values (by 51% in baseline and 36% after
inhibition) with increasing scan durations. This coupled
increase in the VT and decrease in the k2 estimations might
be caused by the accumulation of radio-metabolites in the
brain. As was found for rats and humans, radio-metabolites
formed by the metabolism of (R)-[11C]verapamil can cross the
BBB and accumulate inside the brain. This fact may complicate
the kinetic analysis of the tracer because it is not possible to
differentiate the origin of the radioactive signal (radio-
metabolites or parent tracer). Thus, short PET acquisition
times have been proposed for the analysis of (R)-[11C]-
verapamil.14,49,55 Because K1 is less affected by the scan
duration than VT, we recommend the use of K1 calculated
using 1-TCM and short PET scan durations to measure the P-
gp function at the BBB of nonhuman primates, preferably
accomplished with quantitative perfusion PET studies,
allowing to differentiate between P-gp function and perfusion
changes.
A potential limitation of our study is the small sample size,
though the longitudinal design may reduce the subject
variability and the outcomes show strong and similar inhibitory
effects in all the subjects which emphasize the robustness of
our results. It is also unfortunate that the study did not analyze
lipophilic radio-metabolites in the blood samples. However,
this analysis would require larger volumes of blood during
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blood sampling, which could be harmful to the animals and
lead to errors in the pharmacokinetic analysis. An additional
limitation is the position of the animals in the PET scan. In our
study, the animals were sitting in the PET scan, whereas in
conventional PET scanners, the subjects used to be in a supine
position. This fact may change the biological function of the
animals and thus alter the kinetics of the tracer. Therefore, the
kinetic comparison with other PET studies must be interpreted
with caution. However, this position enables the performance
of the PET scans in conscious unanesthetized monkeys; thus,
anesthetics will not interfere in the distribution of the tracer.56
Moreover, our study did not correct for partial volume effect;
thus, the radioactivity of some small brain regions may be
affected by spillover from regions with high tracer uptake.
This study has provided more insights into the pharmaco-
kinetic parameters of (R)-[11C]verapamil in nonhuman
primates, allowing the comparison with other species. More-
over, these results enable the head-to-head comparison of the
properties of a novel P-gp PET tracer, such as [18F]MC22537
or [11C]metoclopramide,31 with the P-gp tracer, (R)-[11C]-
verapamil, in nonhuman primates, a species larger than rodents
and physiologically more similar to humans.57
5. CONCLUSIONS
Our results suggest that 1-TCM is the model of choice to
analyze the PET data of (R)-[11C]verapamil in nonhuman
primates. The model preference is not affected by scan
duration, and a similar approach should be used in baseline
scans when the P-gp function is fully functional and in scans
after P-gp inhibition. VT and K1 values obtained in nonhuman
primates were different from humans and rats with the same
radiotracer, which highlights P-gp expression differences
among species. However, the rate of (R)-[11C]verapamil
metabolism seems similar in all the species examined. VT was
the parameter most affected by the challenge (P-gp inhibition).
However, because the estimated VT changes with scan duration
and thus cannot be reliably determined, we recommend the
use of K1 calculated with 1-TCM as a suitable parameter to
measure the P-gp function at the BBB of nonhuman primates.
Moreover, short scan durations are recommended to avoid
quantification being affected by the presence of radio-
metabolites in the brain.
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